Research programme: melanin inhibitors - Anaderm
Latest Information Update: 05 Sep 2006
At a glance
- Originator Anaderm Research
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Melanosis
Most Recent Events
- 05 Sep 2006 Discontinued - Preclinical for Melanosis in USA (Topical)
- 03 Oct 2001 Preclinical development for Melanosis in USA (Topical)